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Background: In an adaptive clinical trial (ACT), key trial characteristics may be altered during the course of the trial
according to predefined rules in response to information that accumulates within the trial itself. In addition to
having distinguishing scientific features, adaptive trials also may involve ethical considerations that differ from more
traditional randomized trials. Better understanding of clinical trial experts’ views about the ethical aspects of adaptive
designs could assist those planning ACTs. Our aim was to elucidate the opinions of clinical trial experts regarding their
beliefs about ethical aspects of ACTs.
Methods: We used a convergent, mixed-methods design employing a 22-item ACTs beliefs survey with visual analog
scales and open-ended questions and mini-focus groups. We developed a coding scheme to conduct thematic
searches of textual data, depicted responses to visual analog scales on box-plot diagrams, and integrated findings
thematically. Fifty-three clinical trial experts from four constituent groups participated: academic biostatisticians
(n = 5); consultant biostatisticians (n = 6); academic clinicians (n = 22); and other stakeholders including patient
advocacy, National Institutes of Health, and U.S. Food and Drug Administration representatives (n = 20).
Results: The respondents recognized potential ethical benefits of ACTs, including a higher probability of receiving an
effective intervention for participants, optimizing resource utilization, and accelerating treatment discovery. Ethical
challenges voiced include developing procedures so trial participants can make informed decisions about taking part in
ACTs and plausible, though unlikely risks of research personnel altering enrollment patterns.
Conclusions: Clinical trial experts recognize ethical advantages but also pose potential ethical challenges of ACTs. The
four constituencies differ in their weighing of ACT ethical considerations based on their professional vantage points.
These data suggest further discussion about the ethics of ACTs is needed to facilitate ACT planning, design and
conduct, and ultimately better allow planners to weigh ethical implications of competing trial designs.
Keywords: Adaptive clinical trials, Mixed methods, Ethics, Visual analogue scale, Clinical trials, Qualitative research,
Emergency medicine, Neurological emergency, Informed consent, EquipoiseBackground
Fixed randomized clinical trials (RCTs) are widely
considered the gold standard for determining the rela-
tive efficacy of medical treatments [1]. However, dur-
ing the design of confirmatory trials, even after early
phase exploratory trials have been completed, there is
often substantial uncertainty regarding how best to
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unless otherwise stated.the likelihood of benefit. For example, the optimal
dose of the experimental medication, the best duration
of therapy, or the population most likely to benefit,
may all remain unclear. This situation creates uncer-
tainty as to the optimal parameters for the proposed
trial, yet under the fixed approach to trial design and
conduct, all key trial parameters must be defined before
patient enrollment and then held constant [2].
Adaptive clinical trials (ACTs) represent an innovative
approach to trial design and conduct [3], where the pri-
mary goal of adaptations is to improve scientific value and
statistical efficiency. ACTs are designed to take advantagel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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ters to be modified in response to accumulating data ac-
cording to predefined rules [4-8]. As in all confirmatory
trials that lead to practice change or regulatory approval,
well-designed ACTs follow rigid requirements and are
carefully designed to control the risk of error including
type I and type II error rates [4]. Adaptive designs may in-
corporate a broad spectrum of potential changes to trial
conduct, with early trial termination rules based on statis-
tical boundaries being one of the simplest adaptations.
Most large clinical trials include stopping boundaries
for benefit, futility, or harm; these provide quantitative
guidance to safety monitoring committees [9]. On the
other hand, more complex adaptive trials can be de-
signed to identify the most promising treatments for
specific subpopulations within a disease and tailor trial
enrollment and randomization to maximize the infor-
mation gained [10]. The advantages and disadvantages
of some types of adaptations are better understood than
others. While adaptive designs have existed for some
time, they are receiving renewed emphasis and funders
and oversight bodies have suggested expanded use [11].
Despite the growing interest, few adaptive designs have
been used relative to the overall number of trials con-
ducted. This is especially true in confirmatory phase trials.
In addition, few clinical trialists have actual experience
with adaptive designs and direct knowledge of ACTs.
One prerequisite of conducting any clinical trial is the
careful consideration of the ethics of the trial procedures
[12]. Trial design impacts scientific ethics (it is unethical
to conduct an invalid study), individual ethics (which
patients are allowed to participate and what scientific
and experimental procedures are they exposed to) and
collective ethics (the need to discover better treatments
or treatments for untreatable conditions to improve fu-
ture patient outcomes) [2]. The ethical aspects of fixed
RCTs and ACTs differ. Pullman characterizes the differ-
ence as fixed RCTs favoring collective ethics and ACTs
favoring individual ethics [13]. The statistical focus of
fixed RCTs, particularly those studies designed to change
clinical practice or lead to drug or device approval
(phase III or confirmatory), is to test hypotheses about
treatment effect. In such trials, the primary goal of a trial
is to improve the treatment for the broader community,
with individuals within the trial only conferring benefit if
they are randomly allocated to the better treatment (if
one is indeed found to be better). Through informed
consent, potential research participants decide them-
selves whether to be in a trial, or opt for conventional
therapy [13].
ACTs have different ethical nuances than more trad-
itional, fixed RCTs [14]. In addition to the need for an
informed decision whether to participate in the trial or
choose conventional therapy, there are other ethicalconsiderations. For example, some adaptive design
strategies increase the probability of receiving the more
effective treatment while maintaining the scientific
rigor of the trial [10,15]. This emphasizes individual
ethics because the objective is to treat as many patients
effectively as is possible [13]. The potential advantage
over fixed RCTs is that more patients will be assigned
to the better-performing treatment arm(s), regardless
of which arm(s) that turns out to be. This introduces
one example of a potentially favorable ethical outcome
not present in a fixed RCT. A more recent review
focused on the potential ethical risks of such trial designs,
particularly highlighting the lack of equipoise that de-
velops as the trial goes on and the inherent injustice that
later enrolling subjects will get better treatments than earl-
ier enrolling subjects [16]. A recent article induced a
healthy debate regarding the ethics of one specific form of
adaptive trials: those utilizing outcome (also known as re-
sponse) adaptive randomization [17-22]. Clinical trials in
the critically ill are particularly challenging [23]. Interest-
ing, a hypothetical clinical trial scenario demonstrated
greater participation when participants were offered a trial
with response adaptive randomization [24].
The ADAPT-IT project is an initiative funded by the
U.S. National Institutes of Health (NIH) and the Food
and Drug Administration (FDA). The first aim of the
study is to develop five confirmatory, ACT designs
evaluating treatments for neurological emergencies [10].
For the ACT trial design work, the research team set
out to develop clinical trials focusing primarily on two
broad categories of adaptation, namely, frequent interim
analysis and response-adaptive randomization. Selected
features of these important adaptations are illustrated in
Table 1.
The second aim of the project is to study the ACT
design process itself including the interactions and
views of the constituent clinical design experts [10].
The participating trial experts include clinician re-
searchers, consultant biostatisticians who specialize in
RCTs, academic statisticians who specialize in complex,
multicenter RCTs, regulators from the FDA and NIH as
well as patient advocates (Table 2). Given the complete
lack of empirical literature on clinical trial experts’
views on the ethical aspects of ACTs, the breadth and
diversity among participants in the design process, and
the need for them to work together, this project pro-
vided a unique opportunity to explore clinical trial ex-
perts’ views about the ethical features of ACTs. A better
understanding of their views on ethical features of ACTs
could advance the discussion about ethical aspects of
adaptive designs, identify any areas of contention, pro-
mote dialogue to understand benefits and limitations of
ACTs, and facilitate acceptance of ACTs by the broader
research community.
Table 1 Key features and approaches to adaptations and ethical considerations of frequent interim analysis and
response-adaptive randomization for adaptive trial designs
Trial element Key features How trial is adjusted Comment Ethical considerations
Frequent
interim analysis
(FIA)
• Trial success and futility
are
repeatedly assessed.
• Terminate when successful • Lower total trial size when
treatment is more effective
than anticipated or has little
or no effect
• Ethical advantage accrues as
fewer participants may be
required to terminate a
successful trial or negative trial.
• Provides an ethical advantage for
the population of patients
involved by exposing fewer
participants to ineffective
treatments.
• Terminate if continuation
is unlikely to succeed
• Assess:
• If more participants are needed
when experimental treatment
appears to have marginal
effectiveness, the probability of
benefit will likely exceed 50:50;
this potentially poses an ethical
advantage for the population of
participants because the chance
of getting an effective treatment,
even if marginal, may be greater
than in a trial without FIA
• May increase sample size
per prespecified rules
• May result in a larger
required sample size if
experimental therapy has
marginal effectiveness
− evidence of treatment
efficacy
• Offers ethical advantage by
avoiding erroneous conclusion
that a marginally effective
treatment is ineffective, and
obfuscating use for individuals
who could benefit from
treatment
− rates of adverse events
− patient safety
Response-
adaptive
randomization
(RAR)
• Randomization
proportions are varied
during the course of the
trial.
• Reallocation between arms
to increase the fraction of
participants who receive the
most effective treatment
• Can decrease the required
sample size by allocating
patients in arms most likely
to be efficacious
• Decreasing the sample size offers
ethical advantage to the
population of eligible
participants by exposing fewer
of them to ineffective
treatments.
• Ethical benefits are more likely to
accrue for the population of
patients in the trial as more than
half are likely to be enrolled in
arms with probability of benefit
• Ongoing modification
• Ethical benefit accrues over the
course of the trial for individual
participants, who will be more
likely to receive effective
treatment.
• Allocate patients to
different treatment arms
• Efficiency enhances ethical
benefits for society by
minimizing unnecessary costs
and allowing precious resources
to be re-allocated to other research
for other effective treatments.
• As in randomized,
controlled trials without
RAR, participants enrolled
early have no advantage for
being in an arm with the
more effective treatment,
but enrollment later
enhances probability of
enrollment in the effective
treatment arm
Offers ethical advantage to the
population of persons in society
who need the treatment under
evaluation, since the trial results of
an effective treatment will be
known sooner, providing clinicians
and patients with treatments
known to offer benefit
• Allocate patients to
different doses of an
active agent
• May improve the statistical
efficiency of the trial if there
are more than two arms
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opinions of clinical trial experts regarding their beliefs
about ethical aspects of ACTs. Participants were askedto consider ethical advantages and potential ethical dis-
advantages from the perspective of patients, researchers
and society.
Table 2 Characteristics of clinical trial experts
Characteristic Academic biostatisticians Consultant biostatisticians Academic clinicians Other stakeholders
Mean age 47 45 49 52
Female, 21/53 (39.6%) 3 (60) 1 (17) 5 (23) 12 (60)
Highest degree, 53
MD or equivalent 0 2 (33) 20 (91) 7 (35)
PhD 5 (100) 4 (67) 4 (18) 12 (60)
Primary work location, 52
University/University hospital 5 (100) 1 (17) 21 (96) 3 (15)
Community hospital 0 0 0 0
Government (NIH or FDA) 0 0 0 15 (75)
Consulting firm 4 (67) 1 (5)
Other 0 0 0 2 (10)
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Study design
We conducted a convergent mixed-methods design that
used a 22-item ACT beliefs survey with visual analog
scales (VAS), free-text survey responses, and mini-focus
groups, a type of group interview [25,26]. The VAS in-
strument and the mini-focus group discussion guides are
available as Additional file 1 and Additional file 2. A
mixed methods approach was implemented to elucidate
participants’ beliefs, to identify the reasoning behind the
beliefs expressed, and to integrate the data together to
provide the broadest possible understanding. Study
instruments were developed by an ethicist (MF) and
experts in both traditional and adaptive clinical trials
(WM, RL), and focused on the evaluation of ethical
advantages and disadvantages of adaptive clinical trial
designs. Data were collected with self-administered sur-
veys, either by paper or on the Web, by using VAS and
free-text responses. Reminders were sent to individuals
who had not completed the surveys and frequent an-
nouncements were made during trial planning meetings
encouraging subjects to Data also were collected during
five mini-focus groups with four to six clinical trial
experts per group [25,26]. The mini-focus group guide
was specifically designed with topics to parallel the items
on the VAS instrument so that results from both instru-
ments could be mapped together. The University of
Michigan human subjects review committee deemed this
project exempt from Institutional Review Board over-
sight per United States federal regulations (45 CFR
46.101(b). Participants received information about the
study and the research intent prior to data collection.
Settings and participants
Participants were recruited as part of an ongoing NIH-
FDA–funded research project exploring the incorporation
of ACT designs into an existing neurological emergencies
treatment trials network (NETT) [27]. Project investigatorsheld a series of meetings that included experts in ACT de-
sign and investigators interested in developing an ACT for
specific research topics related to neurological emergencies.
A mixed methods team assessed the ACT development
process during these meetings and conducted the analysis.
Data were collected between January and August of 2011.
Participants were classified as belonging in one of the
following groups of clinical trial experts: academic bio-
statisticians from NIH-funded clinical trial networks (n = 5)
with substantial experience running phase III trials, consult-
ant biostatisticians working in academic or industry settings
with specific experience in Bayesian adaptive designs
(n = 6), academic clinicians (n = 22), and other stake-
holders, e.g., NIH officials, FDA statisticians, medical
officers, and patient advocates — all experts in the
planning of clinical trials (n = 20). Instead we asked
those surveyed for their opinions about how patients
might view the advantages and disadvantages of ACTs.
Variables
Survey and mini-focus group questions were formulated
to gather opinions of the clinical trial experts regarding
the ethical advantages and disadvantages of ACT designs.
Participants considered advantages and disadvantages
from the perspectives of the patient, the researcher, and
society as a whole.
Data sources
Mini-focus groups [25,26] with clinical trial experts were
conducted before the initial face-to-face meetings for
four of the five trials. These mini-focus group sessions
were digitally recorded and transcribed verbatim, and
the data were entered into Atlas.ti v6.0 [28] for data
management.
Participants answered the VAS items by completing a
paper survey or a Web-based survey. The VAS allowed
participants to mark a point of agreement on a con-
tinuum ranging from “definitely not”, to “probably not”,
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100-point scale to allow greater flexibility in examining
differences than a five-point structured Likert scale
would allow. To compute a quantitative measure of a
participant’s assessment, we assigned the lowest anchor
a value of 0 and the highest anchor a value of 100 and
calculated a level of agreement score based on the point
chosen by the participants for the VAS items.Data analysis
Descriptive statistics (proportions and means) were calcu-
lated for demographic variables. The VAS data were
depicted by using box plots visually illustrating the median,
interquartile range, 95% confidence interval, and outliers
for each survey question. Qualitative data from the five
mini-focus groups and free-text responses from the surveys
were analyzed independently by two investigators (LL, SF)
from the mixed-methods evaluation team with an 88%
intercoder agreement [29]. The development of a coding
scheme was based initially on the thematic basis of the
interview guide and revised to reflect the primary themes
that emerged from the analysis. The VAS scores using box-
plot diagrams were integrated with comments by constitu-
ency groups for sub-analyses to merge quantitative ratings
with qualitative textual data and with representative quota-
tions [30]. As a “member check”, the process of allowing
participants in qualitative research to reflect on the findings
and provide the investigators feedback on the extent to
which the findings represent their viewpoints, a near-final
draft of this manuscript was sent to a purposively, chosen
member from each of the four constituency groups—the
academic biostatisticians, the consultant biostatisticians, the
academic clinicians, and the “other” stakeholders group.
These group members responded with suggestions for
wording changes that were integrated into the manuscript.Demographic characteristics of the sample
The survey was offered to 64 participants in the
ADAPT-IT project, of whom 53 individuals participated
from four constituent groups: academic biostatisticians
(n = 5); consultant biostatisticians (n = 6); academic clini-
cians (n = 22); and other stakeholders, including FDA
and NIH personnel and patient advocates (n = 20). The
mean age (± standard deviation) of participants was
49.0 ± 10.9 years. The majority were men (60%) who
were physicians (55%) working in a university hospital
setting (57%). Approximately ten individuals who were
participants in the survey procedures were also co-
investigators on the ADAPT-IT project; these individuals
were not directly involved in the data collection or
analysis of the textual and survey data; several were
involved in the criticial revision and interpretation
presented in this manuscript.Results
Figures 1 and 2 illustrate stakeholders’ opinions of the
ethical advantages and potential disadvantages of ACTs
when considered from the patient, researcher, and societal
perspectives. The section on the left side of each figure pro-
vides the participants’ ratings of the ethical advantages on
the VAS, with the lowest anchor at 0 to signify definitely
not agreeing with the statement and the highest anchor at
100 to signify definite agreement with the statement. In
addition, the right side of each figure features illustrative
opinions from the free-text response on the survey and the
mini-focus groups.
Potential ethical advantages of ACTs
Opinions regarding the patient perspective
The consultant biostatisticians, academic clinicians, and
other stakeholders rated the effects of ACTs on patients
as definitely advantageous to probably advantageous,
whereas academic biostatisticians’ responses ranged
from possibly having to probably not having ethical
advantages (Figure 1). Participants suggested that the
greatest advantage from the patient’s perspective fo-
cused on the potential benefit to the study patient. A
member of the “other” stakeholder group offered an il-
lustrative response regarding the favorable benefit: “Re-
sponse-adaptive randomization gives patients a better
chance of being randomized [to the better arm in a clin-
ical trial]”. Another participant, a clinician, raised the
point that ACTs will not expose more people than ne-
cessary to an ineffective drug: “[The] main ethical advan-
tage is that you potentially reduce the number of patients
who get the ineffective drug, and that actually is a plus”.
Consultant biostatisticians highlighted the importance of
understanding the individual ethics of a trial:
“The adaptive approach, when properly done, pays more
attention to individual ethics, in the sense that it ensures
that the trial doesn’t continue when there isn’t a chance
that either therapy is effective or that the therapy is more
effective than the control. It can be designed to improve
the outcomes of patients within the study”.
Academic biostatisticians also thought there was a po-
tential benefit to response-adaptive randomization, as one
opined, “The idea of response-adaptive randomization is
to let later patients have a higher likelihood of getting a
drug that seems to be working better”. One patient advo-
cate suggested that the advantage to an ACT is that it is a
new approach,
“Whether or not an adaptive trial really offers ethical
advantages, patients will perceive "a new and different"
approach aimed at time issues and increased
communications as progressive”.
Clinical trial expert opinions on ethical advantages to adaptive clinical trials 
Opinions on potential ethical advantages of adaptive trials from patient perspectives
Consultant Biostatistician:
 When done well they [ACTs] treat patients in and out of the trial better (Survey) 
 [The complexity of understanding an ACT informed consent] I think it’s a false concern.  
When you do studies that people have consented for traditional clinical trials, [people feel] 
the purpose of the trial is to improve their individual outcome, and the number who in any 
kind of quantitative way understand the randomization is very low.  (MFG) 
Clinician: 
 I think it only makes sense that if you are going to avoid exposing subjects to ineffective 
therapies that that’s the ethically obligatory thing to do. (MFG)  
 There is no problem explaining to patient that if we find one arm to be clearly inferior we 
drop it, and one to be clearly superior we’ll stop [the trial] early. (MFG) 
Other Stakeholder:  
Whether or not an adaptive trial really offers ethical advantages (random) patients will 
perceive "a new and different" approach aimed at time issues and increased 
communication as progressive (Survey)
Academic Biostatistician:
It depends on the design, but it may be more advantageous to have a higher probability 
of being randomized to the active arm. (Survey)
Opinions on potential ethical advantages of adaptive trials from the researchers’ perspective
Consultant Biostatistician:  
  [Researchers] can create [trial] designs that learn more and treat better with less burden 
and sacrificing of patients for research. (Survey) 
 [When a trial is a loser, there can be a] redistribution of intellectual capital. (MFG) 
Clinician:  
  [ACT designs] improve our ability to talk to patients about how ethical and beneficial it is 
to be in a clinical trail. (MFG)
 [ACT designs] conserve resources and protect patients exposed to the poor treatment 
(Survey) 
Other Stakeholder:  
  [Using an ACT], allows research to adapt to current trends (Survey) 
Ethics of the trial is based on the soundness of the science of the trial design; if the trial 
is designed so that a valid result is obtained, there appear to be significant ethical 
advantages to adaptive designs, particularly in terms of reducing sample size and 
exposing subjects to inferior treatments for a shorter amount of time. (Survey)
Academic Biostatistician:
 We [as researchers] have an ethical obligation to design best possible trial. (MFG) 
Opinions on potential ethical advantages of adaptive trials from a societal perspective
Consultant Biostatistician:  
 Fewer patients are "used" to identify ineffective therapies freeing them up for trials of 
potentially effective therapies.  Also effective therapies can get to market faster. (Survey)
 It’s really better for everybody if you’re adaptively making decisions and it’s leading you 
to the best treatment it’s better for the patients in the trial. (MFG) 
Clinician: 
 ACT designs have the opportunity to be a better trial design and a better design is always 
more ethical. (MFG)  
 If we end up with an ACT that reduces the overall number recruited, I think that the 
community would be more supportive; we changed the design so fewer people are going 
to be exposed to the less effective drug. (MFG)
Other Stakeholder:  
 Consider the economic concerns of the health care industry. Again, there is a potential 
that adaptive designs could provide an advantage when used appropriately. (Survey) 
IF they're rigorous they can shorten trials, lead to success. (Survey)
Academic Biostatistician:
If we use adaptive design, maybe we can save some time by adding or dropping a 
treatment arm.  So, that way we can shorten the total time. That maybe a benefit to the 
entire society (MFG)
Figure 1 Clinical trial expert opinions on ethical advantages to adaptive clinical trials from the patient, researchers, and societal perspectives. The
above Likert scales anchor from 100 (definitely) to 0 (definitely not). Boxplots represent median and inter-quartile range. Responses are colored by
respondent type as are boxplots.
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Three groups assessed the ethical advantages from re-
searchers’ perspectives positively, with ratings in the range
of definitely to probably among consultant biostatisticians
and probably to possibly among the academic clinicians
and other stakeholders (Figure 1). One clinician noted that
ACT designs:
“make me feel like it improved our [clinician’s] ability
to talk to the patient about how ethical and beneficial
it is to be in clinical trials. So, again, assuming thatwe’re talking about pre-specified changes, I think it
would - there would be substantial ethical issues if we
told the patients we’re going to put you in the trial,
and we may change the eligibility criteria; we may
change the outcome criteria; we may change everything;
we have no idea where we’re going with this. I don’t
think that that is a fair thing to put a patient into.
But if we’re talking about adaptive clinical trials
where we are pre-specifying what our adaptations
are, I think that that’s a very beneficial thing to
patient care”.
Clinical trial expert opinions on ethical disadvantages to adaptive clinical trials 
Opinions on potential ethical disadvantages of adaptive trials from patient perspectives
Consultant Biostatistician:  
 It’s an adaptive design, randomization or allocation may be changing, things in the 
design may be changing, that you can’t appropriately inform them on the informed 
consent, of what they’re signing up for, and that these are possible issues, ethical issues 
as to do you update, what do you need to inform them about the design, and is it enough 
to say, we’ll adaptively allocate 
Clinician:  
 Only if they [the trial design team] reject treatments too early (Survey)
 It may be clear that one treatment group is looking to be more effective, but they don’t 
have enough patients in one of the other arms, as many as they would like to have, and so 
some of the patients may get assigned to that other arm, because they need more 
patients in the arm, even though it doesn’t look like that arm is the more effective arm. 
(MFG)
Other Stakeholder:  
I can only see it would [affect the patient] if it was unblinded (Survey)
Academic Biostatistician:
 Patients who are enrolled early are going to be treated differently than the ones that all 
enrolled late because you’re changing the design midcourse (MFG) 
There’s too many parameters that you have to consider in informed consent so I think that 
could be a bear. (MFG)
Opinions on potential ethical disadvantages of adaptive trials from the researchers’ perspective
Consultant Biostatistician:  
 Potential greater concerns about unblinding if appropriate firewalls aren't in place. 
(Survey) 
Clinician: 
 Adaptive trials are going to be inherently less transparent; less transparency is always a 
little more – raises an ethical concern then because it’s harder to check people, so 
there’s an ethical concern that goes with that. (MFG) 
 [If a] trials funded for 5 years, and the trial ends early [because] no change of findings, 
[researchers] can't keep research staff which is a problem (Survey) 
Other Stakeholder:  
  Not necessarily more or less (Survey) 
Academic Biostatistician:
It gives [ACT trial design] the investigator some kind of hint, which is working better, 
which could lead to selection bias. (MFG) 
Informed consents are long already but if you really want to inform your subjects, what 
the study is you’re going to have to explain all of the “adaptation” that you’re planning. 
(MFG)
Opinions on potential ethical disadvantages adaptive trials from a societal perspective
Consultant Biostatistician:  
 None 
Clinician: 
 There are trust issues with adaptive trials, because of the somewhat diminished 
transparency requiring more trust; EIFC (exception from informed consent) trials require 
more trust.  If there is a lack of trust then it’s going to be a problem for both EIFC trials 
and adaptive trials, and if there’s a lack of trust then try to do both, and it’s just another 
front for the trust problem (MFG)  
 Only if treatments are inappropriately rejected too early (Survey) 
Other Stakeholder: 
 Don't think public opinion will understand difference [between a traditional trial design 
and an ACT]. (Survey) 
Academic Biostatistician:
I think if ACTs get the wrong reputation of things happening faster, it could get a little 
sticky if they don’t educate the public enough. So then if there’s a misperception of what 
adaptive designs do I could see where that could snowball into chaos if something went 
wrong (MFG)
Figure 2 Clinical trial expert opinions on ethical disadvantages to adaptive clinical trials from the patient, researchers, and societal perspectives.
The above Likert scales anchor from 100 (definitely) to 0 (definitely not). Boxplots represent median and inter-quartile range. Responses are col-
ored by respondent type as are boxplots.
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ety in this case, participants also pointed to other
advantages of ACTs versus a more traditional RCT
without reallocation, including, as noted by a con-
sultant biostatistician,
“there’s the intellectual capital that can get wasted. If
all of your statisticians and your study people are no
longer focusing on this trial that’s a loser, they can be
working on something else. So I think that the overall
efficiency of the medical research enterprise is
something that ought to be important to all of us in
the adaptive design part”.Academic biostatisticians rated the ethical advantages
to be in the range of possibly advantageous to probably
not advantageous.
Opinions from a societal perspective
Regarding opinions from a societal perspective, the
consultant biostatisticians all indicated definite ethical
advantages. Responses from the academic clinicians and
other stakeholders ranged from probably to possibly of-
fering advantages, and the academic biostatisticians from
possibly offering advantages to probably not offering ad-
vantages (Figures 1 and 2). Some participants identified
specific advantages from the societal perspective, such
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stakeholder). One consultant biostatistician suggested:
“fewer patients are "used" to identify ineffective
therapies freeing them up for trials of potentially
effective therapies. Also effective therapies can get to
market faster. Plus were more likely to have a better
dose make it to market.,” (consultant biostatistician).
An academic biostatisticians opined:
“If we use adaptive design, maybe we can save some
time by adding or dropping a treatment arm. So, that
way we can shorten the total time. That maybe a
benefit to the entire society [for the patient or the
trial], I don’t think it’s ethical either good or bad thing.
It could be either”.
Potential ethical disadvantages of ACTs
Opinions regarding the patient perspective
More than the other groups, academic biostatisticians
assessed the ethical disadvantages of ACTs for patients
to be high; their VAS responses ranged from probable
disadvantages to definite disadvantages. Citing time of
enrollment, one academic biostatistician stated, “Patients
who are enrolled early are going to be treated differently
than the ones … [who are] enrolled late, because you’re
changing the design midcourse”. The academic biostatis-
ticians also expressed concerns about informed consent:
“I think it will be a mess, the informed consents are
long already but if you really want to inform your
subjects, potential subjects, what the study is you’re
going to have to explain all of that adaptations that
you’re planning. So then to explain how your chances
are going to change during the course of the study, it
definitely could complicate”.
The clinician group and the “other” stakeholder group
assessed potential disadvantages with lower scores; they
generally perceived that patients would probably have no
disadvantages, unless “treatments were rejected too early”
(clinician) or “if the process was unblinded” (other stake-
holder group). Consultant biostatisticians indicated that
ACTs had no definite disadvantages to patients, however
one acknowledged that informed consent was a compli-
cated issue:
“an adaptive design, randomization or allocation may
be changing, things in the design may be changing,
that you can’t appropriately inform them [patients] on
the informed consent, of what they’re signing up for,
and that these are possible issues, ethical issues as to
do you update, what do you need to inform themabout the design, and is it enough to say, we’ll
adaptively allocate. We don’t change the informed
consent when the randomization changes. We tell
them that this will be adapted in the following way.
They may not understand it, but which patient does
understand the protocol and be informed, is truly
informed”.
Opinions regarding the researcher perspective
All four constituent groups rated adaptive trials as having
few potential ethical disadvantages when considered from
the researcher’s perspective (Figure 2). Ratings from the
researcher’s perspective ranged from possibly to probably
not among other stakeholders, probably not among the
academic clinicians and academic biostatisticians, and
definitely not among the consultant biostatisticians. In
mini-focus group discussions among academic biostatisti-
cians, concern was raised about the risks of unintentional
unblinding that could occur and how this could lead to se-
lection bias from academic clinicians who might then con-
sciously or unconsciously steer particular patients away
from enrolling in the trial. Noted one such participant,
“[ACT design] gives the investigator some kind of hint
[regarding] which [treatment] is working better [and]
which could lead to selection bias because now one is
better than the other side. The investigator may
purposely enroll or reject a potential subject for or
against a specific arm (academic biostatistician)”.
Consultant biostatisticians acknowledged that unblind-
ing might be an issue, especially if “appropriate firewalls
are not in place” to prevent it. Clinician stakeholders
thought that ending a trial early could be a disadvantage
if doing so led to a loss of funding, resulting in an inabil-
ity to “keep research staff, which is a problem”. This sen-
timent illustrates a potential conflict of interest for a
funded investigator, as an ACT conducted with an early
stopping rule could put an investigator at a financial dis-
advantage if grant funding ends earlier than anticipated.
The “other” stakeholder group did not indicate any dis-
advantages from the researcher perspective.
Opinions from a societal perspective
Three of the constituent groups—the academic clinicians,
other stakeholders, and academic biostatisticians—rated
disadvantages of ACTs from a societal perspective in a
range of possibly to probably not disadvantageous, whereas
the consultant biostatisticians rated ACTs as definitely not
having ethical disadvantages from this perspective
(Figure 2). One clinician commented that the only dis-
advantage would be if “treatments were inappropri-
ately rejected to early”. A member of the “other”
stakeholder group “didn’t think that public opinion
Legocki et al. BMC Medical Ethics  (2015) 16:27 Page 9 of 12would understand the difference” between an adaptive
and a traditional design.
Trends according to intragroup and intergroup variations
across all ethical questions
Across all the ethical domains provided (Figures 1, 2
and 3), the intragroup variation was least among the
consulting biostatisticians, although this group had the
fewest participants. Regarding intergroup comparisons,
the academic clinicians and other stakeholders had
roughly similar patterns of rankings of the ethical advan-
tages and disadvantages of ACTs from the participant,
researcher, and societal perspectives. The consultant bio-
statisticians took positions similar to those of the academic
clinicians and other stakeholders on the ethical advantages
and disadvantages across all scenarios, although their
ratings more strongly emphasized the ethical advan-
tages and deemphasized ethical disadvantages. On the
other hand, the academic biostatisticians had some
overlap with the academic clinicians and other stake-
holders, but their anchor points deemphasized ethical
advantages and emphasized ethical disadvantages. Over
all, intergroup differences were greatest between the
academic biostatisticians and the consulting biostatisti-
cians, as they rated oppositely on five of the six ratings,
and the tails of their responses on the box plots did not
overlap, meaning their ratings differed by more than
two standard deviations.
Discussion
This is the first known empirical study of clinical trial
experts’ views on ethical issues in adaptive clinical trials.
Previous normative work has debated the ethical con-
struct of clinical trials, and how adaptive clinical trials
represent areas where the ethical issues may change
based on design features [13,16]. The major concerns
raised in these describe a tension between collective ethics
(trial validity versus efficiency) and individual ethics (ex-
posure to a better treatment versus fairness of enrolling
early versus late in a clinical trial.) A great deal of recent
discussion in the clinical trials literature has focused on re-
sponse adaptive randomization in two-arm trials; however
this represents a fairly specific and relatively infrequently
used type of ACT [17-22]. Our current investigation
builds upon this understanding, and directly examined the
opinions of vested stakeholders in the development of
ACTs under a special grant from the NIH and FDA to
accelerate new discoveries and translate findings into
practice [27]. While there were some similar patterns
of agreement and disagreement, there were substantive
intra-group and inter-group variation. Given that all stake-
holders— clinicians, biostatisticians, and others—must
work together, understanding the anchor points and
values of these groups relative to the potential ethicaladvantages and disadvantages of ACTS is important
for the collaborative efforts needed to make these tri-
als a reality.
Areas of agreement across stakeholders
Although textual data illustrated many similarities in the
understanding of ethical issues of ACTs, the VAS scores
demonstrate different anchor points among different
stakeholder groups on the relative importance of the
ethical advantages and disadvantages of ACTs. The
constituent groups agreed that ACTs, including response-
adaptive randomization and dropping futile arms, would
have ethical advantages for patients. Use of ACTs can help
avoid exposing some participants to ineffective treatments,
thus offering a clear ethical advantage. For example, the
constituent groups agreed that “killing bad drugs” soon-
er—that is, leveraging the strengths of ACTs to evaluate
drugs that do not have potential and ending such trials
early—provides ethical advantages. In addition, the ethical
advantages of dropping a treatment as soon as possible,
and stopping the trial as soon as possible when a treat-
ment is found to be superior, merit highlighting. All stake-
holders agreed that adaptations need to be prespecified,
and that having a clear understanding of what is being
changed or “adapted” is prerequisite for conducting a
valid, and hence ethical, ACT.
Response-adaptive randomization
The point was raised that under response-adaptive
randomization, individual participants enrolled early, be-
fore any adaptation, would not achieve any additional
benefit (or any harm), compared with a trial that lacks
response-adaptive randomization or has fixed-interval
analysis. However, it is clear that a greater proportion of
individuals over the course of a response-adaptive ran-
domized trial would be expected to receive the effective
treatment if there ultimately was a more effective treatment
being tested. In short, at the population level, participation
in an ACT confers an ethical advantage over the course of
the trial.
Unintentional unblinding and biased enrollment
The participant groups identified potential risks and
hence potential ethical disadvantages of ACTs. For ex-
ample, if information about the results of interim analyses
were leaked or inferred by clinicians involved in recruiting
potential participants, bias could be introduced if the clin-
ician then chose to enroll or not enroll patients on the
basis of the information being leaked. For example, in a
trial with RAR that is searching for the optimal duration
of hypothermia exposure in spinal cord injury, there
would be concern for investigator bias if clinician investi-
gators noted that patients at their clinical center/site were
being allocated to longer durations of hypothermia. Such
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ing assigned, e.g., in an unblinded trial like the spinal cord
trial, but also enrollment at their site is relatively high
since they won’t necessarily know about enrollment in
other sites.
The clinician stakeholders in this study primarily work
on multicenter trials in emergency settings where dis-
cerning patterns of treatment assignment to different
arms of a trial seems unlikely because the actual number
of subjects in a given site will be relatively small, even if
the trial is unblinded. The concern may be real in open-
label trials in which the number of patients in one or
more participating centers is large.Informed consent
Participants disagreed on whether informed consent
would be more complex in ACTs. Existing data suggest
that when current informed consent procedures are
used, participants consistently fail to grasp the difference
between research and treatment, even when there is
fixed 1:1 randomization [10]. Thus, the addition of fur-
ther complexity in an ACT featuring response-adaptive
randomization of participants to what appears to be the
more effective arm or explaining fixed-interim analysis
could appear to increase the complexity of informed
consent decisions [31]. Discrepancies in views about this
may reflect different value judgments about a “forest
versus trees” understanding of the study. If a researcher
believes that potential participants must understand the
details of the allocation procedure (e.g., response-
adaptive randomization) or interim analyses, then the
informed consent process could be more difficult. If,
alternatively, a “forest” (“big picture”) approach to ex-
planation is followed, then the informed consent
process may not provide significantly greater chal-
lenges. Among the authors with the most experience in
trials using adaptive designs (DB, RL), informed con-
sent has not felt to be substantively more challenging
with ACT studies, compared with non-adaptive trials.
Future research could explore empirically the difficulty
of achieving informed consent in trials that do and do
not use adaptive designs. The concept of individual
fairness (enrolling early versus late in a ACT), was not
substantially explored by this group of stakeholders.
Since the ADAPT-IT project focused on neurological
emergencies (stroke, spinal cord injury, brain injury fol-
lowing cardiac arrest etc.) and others had substantial
oncology experience (cancer patients are unlikely to
delay treatment to get a better chance in an ACT) this
general concept was not frequently discussed as it is
not possible to delay the occurrence of one’s cardiac
arrest so as to have a better chance at getting a new
treatment in a clinical trial.Respondent group variations
Some considerations may help explain the differences
between the two biostatistician groups. First, the consultant
biostatisticians may have been focusing explicitly on
response-adaptive randomization and frequent interim ana-
lyses in the context of clear stopping rules, as these ele-
ments of high-quality trials are the primary focus of their
work. In contrast, the academic biostatisticians may have
been considering a broader variety of adaptations and other
trial conduct aspects such as maintaining the blind, proto-
col violations, and implementation of the adaptations. Con-
cerns about the potential biases introduced by unfamiliar
types of adaptations may have led academic biostatisticians
to generally be more cautious, whereas the consultant
groups have more frequently simulated, designed, imple-
mented and analyzed such designs and therefore have less
concern about certain forms of potential statistical biases
given past experience.
Second, the perspectives on ethical advantages/disad-
vantages may be highly correlated with experiences in
the design and conduct of the more complex adaptive
designs. As stated in the FDA guidance, the more com-
plex designs are less understood which may impact the
assessment of ethical perspectives. Professional groups,
consultant biostatisticians, academic clinicians, academic
biostatisticians, and other stakeholders, alike, will make
ethical judgments based on their own experiences and
professional lenses. For example, consultant biostatisti-
cians bring to the table an approach relying heavily on
Bayesian modeling and decision-making. The academic
biostatisticians’ views may reflect their experience in the
logistical and operational aspects of trials—for example,
the complexity of informed consent, protocol deviations
and risks for operator bias.
Study limitations
This study involved a relatively small, but experienced
group of clinical trial experts actively developing rigor-
ous clinical trials, although importantly many had little
experience with ACT designs. Although this research
elicited opinions from various stakeholders regarding the
performance of ACT designs, caution should be heeded
when extrapolating these opinions to others of the same
constituencies or assuming their representativeness in
the broader biomedical community. We did not survey
institutional review board members, as the ethics review
of trials typically occurs after the design phase we focused
on, although this would be an interesting area for further
study. In addition, medical ethicists would have been able
to provide a broader consideration of the ethical issues in-
volved in ACT planning and implementation and would
be important to include in future studies. In retrospect, it
may have been beneficial for the respondents to consider
the ethical aspects of ACTs within the full Emanuel
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favorable benefit-risk ratio, independent review, informed
consent, and respect for the research subjects) [32].
Designers of ACTs may do well to consider these seven
elements when comparing a proposed ACT to a more
traditional fixed trial in the planning process. In
addition, greater involvement of patients or patient ad-
vocates is an important part of the trial process and
should be included early in the planning of any type of
clinical trial [33]. Finally, the expressed opinions on a
range of ethical issues come from four constituent
groups with widely variable experience and familiarity
with ACTs.
Conclusions
We found substantive differences in views on the ethical
aspects of ACTs within and across the key constituencies
of consulting statisticians, academic statisticians, academic
clinicians, and other stakeholders such as regulators and
patient advocates. Collectively, the clinical trial experts
participating in this study identified many of the ethically
advantageous and potentially challenging aspects of ACTs
that are already well known to specialists in this type of
trial design. However, at an individual level, perspectives
on the ethical advantages and disadvantages of ACTs
varied considerably. The four constituencies differ in
their weighing of ACT ethical considerations based on
their professional vantage points. As a starting point,
these data suggest there may be substantive differences
in the opinions of key stakeholder constituencies that
need to work together to conduct ACTs. Thus, it would
seem that data suggest further discussion about the
ethics of ACTs is needed to facilitate the moral buy-in
that achieves effective teamwork in ACT design and
conduct, and ultimately accelerates movement of effective
therapies from bench to bedside.
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